Aldaver

Aldaver (ALDAVER) is a Korean company that develops next-generation medical simulators built from advanced biopolymer materials. Using biopolymer synthesis combined with 3D printing, it manufactures artificial organs used both in medical device development and in surgical training simulators. According to reporting on its Series A round, the company's artificial organs replicate the mechanical and electrical properties of real organs, and medical professionals involved in testing have identified them as a potential alternative to the live pigs currently used in surgical simulation.

The company's initial simulator products address urology, and it has stated plans to extend the line into laparoscopy, with a longer-term aim of covering all human organs. Research reported at the time of the round was directed at reproducing not only organ structure and texture but also blood flow and fine muscle movement. Kim Jin-oh is identified as co-CEO.

Business model

Aldaver manufactures artificial organ products for medical device companies and for surgical training simulators, producing them at its own facility in the Osong High-Tech Medical Complex.

Traction

Its artificial organs have been tested at 10 training centers across six countries in collaboration with global medical device companies. The company reported development requests and interest from global medical device firms and planned to begin proof-of-concept testing with them in the year following its Series A.

Latest developments

In December 2024 the company announced an $8.4 million (KRW 11 billion) Series A from SL Investment, Korea Investment Partners and DAYLI Partners, with follow-on participation from KB Investment and Ascendo Ventures. It said it would use the capital to fully operate its Osong manufacturing facility, expand from urology simulators into laparoscopy, begin proof-of-concept testing with global medical device companies, and recruit global marketing staff.